http://www.lsis.com/goto/r98/rss 2010-06-23T11:10:58+01:00 text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v98/%3B%97f%FB%1Cu%7Dy PRINCETON, N.J. & WILMINGTON, Del.-(BUSINESS WIRE)-Findings from a 24-week Phase 3 clinical study published online in the latest issue of Diabetes Care demonstrated that the investigational drug dapagliflozin, administered as a monotherapy, achieved statistically significant mean reductions at 5 mg and 10 mg doses once daily in the primary endpoint of glycosylated hemoglobin levels (HbA1c) in treatment-naïve adult patients with newly diagnosed type 2 diabetes, compared to placebo. The study also showed reductions in the secondary endpoint of fasting plasma glucose (FPG) and total body weight compared to placebo in these patients. Signs, symptoms and other reports suggestive of urinary (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v98/%3B%97f%FB%1Cu%7E%7B CAMBRIDGE, Mass.-(BUSINESS WIRE)-Ensemble Discovery today announced that it will begin operating as Ensemble Therapeutics Corporation to reflect the Company s progress and emerging pipeline by applying its macrocycle drug platform to develop novel therapeutics. The new name, Ensemble Therapeutics, conveys the company s leadership and advancement in developing novel macrocycle drug compounds that are small molecules with expanded therapeutic properties of large molecule biological drugs. We also are delighted to announce the addition of Kisco Ltd. to our syndicate of top-tier investors. As an advanced materials specialty company, they have keen eye for innovative technologies and found (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v98/%3B%97f%FB%1Dt%7Bx For an amorphous drug-polymer solid dispersion, a distinctive single T(g) intermediate of the two T(g) values of the two components has been widely considered as an indication of the mixing uniformity, which is critical for the stability of the amorphous drug against crystallization. In this study, two batches of amorphous solid dispersions consisting of BMS-A, a poorly water-soluble drug, and PVP-VA, were made by a twin-screw hot-melt extruder using different processing conditions. Both batches displayed an identical distinctive single T(g) that is consistent with the prediction of Fox equation assuming homogeneous mixing of the two components. Neither DSC nor PXRD detected any drug (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v98/%3B%97f%FB%12yvs The control of crystalline and amorphous phases is important during the development of a new drug candidate. Our approach begins with an understanding of the thermodynamics of these two phases. We have developed a quantitative yet practical work flow consisting of three steps towards the analysis of the risk of amorphous material formation. First, we derive the thermodynamic equations to calculate the enthalpy, Gibbs free energy, and the solubility of each phase and their differences as a function of temperature. The enthalpy for each crystalline drug substance at its melting point is selected as the reference state to enable a consistent approach for all analysis. Second, we use data from (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v98/%3B%97f%FB%11u%7D%7F SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (Nasdaq:EXEL) will provide an update on its collaboration with Bristol-Myers Squibb Company for XL184 on Monday, June 21, 2010 before the markets open. The announcement will be followed by a live webcast at 5:00 a.m. PT/ 8:00 a.m. ET. The webcast may be accessed in the Event Calendar page under Investors at http:/www.exelixis.com. An audio replay of the webcast will be available until 11:59 p.m ET/ 8:59 p.m. PT on July 5, 2010. Access numbers for the replay are: 888-286-8010 (domestic) and 617-801-6888 (international), and the passcode is 21140740. About Exelixis Exelixis, Inc. is a development-stage biotechnology company (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v98/%3B%97f%FB%11u%7C%7E SAN DIEGO-(BUSINESS WIRE)-Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it will webcast its Investor and Analyst Day at the Eventi hotel in New York City on June 24, 2010 from 4:15 p.m. to 5:45 p.m. Eastern time (1:15 p.m. to 2:45 p.m. Pacific). Overview of Muscle Disorders/Wasting and the Role for a SARM Therapeutic Presenters will include: John Higgins, President and Chief Executive Officer John Sharp, Vice President of Finance and Chief Financial Officer Robert McKay, Associate Director of Business Development Syed Kazmi, PhD, Vice President of Business Development Nezam Afdhal, MD, Chief of Hepatology, Beth Israel Deaconess in Boston œPresentation on (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v98/%3B%97f%FB%11u%7Fx SCHAUMBURG, Ill.-(BUSINESS WIRE)-APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ: APCVZ) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Aztreonam for Injection, USP in two dosage strengths. Aztreonam is therapeutically equivalent to the reference-listed drug Azactam, which is marketed by Bristol-Myers Squibb. The approval of APP s Aztreonam marks the first generic entrant into the market and provides clinicians with an alternative to the branded drug APP will launch Aztreonam immediately in single dose vials of 1 gram, 20 mL and 2 gram, 30 mL. APP's Aztreonam is (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v98/%3B%97f%FB%11t%7E%7C SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (Nasdaq:EXEL) will provide an update on its collaboration with Bristol-Myers Squibb Company for XL184 on Monday, June 21, 2010 before the markets open. The announcement will be followed by a live webcast at 5:00 a.m. PT/ 8:00 a.m. ET. The webcast may be accessed in the Event Calendar page under Investors at http:/www.exelixis.com. text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v98/%3B%97f%FB%11t%7Es SCHAUMBURG, Ill.-(BUSINESS WIRE)-APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ: APCVZ) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Aztreonam for Injection, USP in two dosage strengths. Aztreonam is therapeutically equivalent to the reference-listed drug Azactam, which is marketed by Bristol-Myers Squibb. text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v98/%3B%97f%FB%11t%7Ex SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company (BMS) entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials. Given the recent progress of BMS wholly-owned oncology pipeline and positive data generated by XL184, Exelixis and BMS were not able to align on the scope, breadth and pace of the (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v98/%3B%97f%FB%11%7Bx%7D BETHLEHEM, Pa.-(BUSINESS WIRE)-Saladax Biomedical, Inc. (www.saladax.com) announced today that it has entered into a multi-year development and commercialization agreement with Bristol-Myers Squibb Company (NYSE: BMY - News) for the development of certain clinical diagnostic tests to be used in conjunction with the development of certain therapeutic compounds in the Bristol-Myers Squibb pipeline. œThis collaboration demonstrates our capability to develop clinical diagnostics with a leading global pharmaceutical company such as Bristol-Myers Squibb,  said Dr. Salvatore Salamone, CEO of Saladax. œThe breadth and flexibility of Saladax s core scientific capabilities can be applied (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v98/%3B%97f%FB%11z%7C%7E SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (Nasdaq:EXEL) will provide an update on its collaboration with Bristol-Myers Squibb Company for XL184 on Monday, June 21, 2010 before the markets open. The announcement will be followed by a live webcast at 5:00 a.m. PT/ 8:00 a.m. ET. The webcast may be accessed in the Event Calendar page under Investors at http:/www.exelixis.com. An audio replay of the webcast will be available until 11:59 p.m ET/ 8:59 p.m. PT on July 5, 2010. Access numbers for the replay are: 888-286-8010 (domestic) and 617-801-6888 (international), and the passcode is 21140740. About Exelixis Exelixis, Inc. is a development-stage biotechnology company (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v98/%3B%97f%FB%17%7Ey%7B In a quantitative trait locus (QTL) study, it is usually not feasible to select families with offspring that simultaneously display variability in more than one phenotype. When multiple phenotypes are of interest, the sample will, with high probability, contain 'non-segregating' families, i.e. families with both parents homozygous at the QTL. These families potentially reduce the power of regression-based methods to detect linkage. Moreover, follow-up studies in individual families will be inefficient, and potentially even misleading, if non-segregating families are selected for the study. Our work extends Haseman-Elston regression using a latent class model to account for the mixture of (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v98/%3B%97f%FB%14%7Fx%7C The U.S. Food and Drug Administration approved a new indication for Tasigna (nilotinib) for the treatment of a rare blood cancer when it is first diagnosed. The cancer, called Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ CP-CML), is a slowly progressing blood and bone marrow disease linked to a genetic abnormality. Tasigna is believed to work by blocking a signal that leads to leukemic cell development. The new indication expands the use of Tasigna to adult patients in earlier stages of the disease. The FDA originally approved Tasigna in October 2007 for the treatment of Ph+CP-CML in adult patients whose disease had progressed or who could not tolerate other (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v98/%3B%97f%FB%14%7E%7Dy SEATTLE-(BUSINESS WIRE)-ZymoGenetics, Inc. (NASDAQ:ZGEN) today announced that Lars Fruergaard Jørgensen of Novo Nordisk A/S was elected to the company s Board of Directors at the annual meeting of shareholders. He replaces Lars Rebien Sørensen, a previous Novo Nordisk representative, who resigned from the Board in March 2010. Novo Nordisk holds approximately 27% of the company s outstanding shares. We look forward to his participation and contribution in the coming years. "Lars Fruergaard Jørgensen brings to our Board many years of operational, financial and strategic experience in the global pharmaceutical industry," said Bruce L.A. Carter, Ph.D., Chairman of the Board of (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v98/%3B%97f%FB%14%7E%7Cz OTTAWA-(BUSINESS WIRE)-At its 2010 annual general meeting in Montreal yesterday, the national biotechnology association, BIOTECanada, confirmed a national team of industry leaders, whose expertise will ensure Canada keeps growing what today is an $84 billion bio-economy. As we face a new wave of technological innovation across agri-business and industrial and environmental biotechnologies, I am pleased to join this pan-Canadian group of industry leaders in raising awareness of the value our technologies bring to Canada s future The cross-sectoral team comes from companies across the country involved in industrial, agricultural, and health biotechnology including: crop DNA modification, (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v98/%3B%97f%FB%14%7E%7Fs DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/6a3e9b/bristolmyers_squi) has announced the addition of the "Bristol-Myers Squibb Co in Consumer Health - World" report to their offering. Bristol-Myers Squibb Co in Consumer Health - World This report analyses Bristol-Myers Squibb's consumer health operations, with a particular emphasis on the impact of its growing focus on BioPharma and the most effective ways to realise the potential of its consumer health business in line with its core strategy. The Bristol-Myers Squibb Co in Consumer Health company profile offers detailed strategic analysis of the company's business, examining its performance in (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v98/%3B%97f%FB%14%7E%7F%7D DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/d7d20e/discovery_stage_pa) has announced the addition of the "Discovery Stage Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, 2nd Edition" report to their offering. Discovery Stage Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, 2nd Edition The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report detailed understanding and analysis of how and why companies enter discovery stage licensing/business development and other forms of partnering arrangement. The report provides a detailed understanding and analysis of how and why companies enter (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v98/%3B%97f%FB%14%7Dzs Despite an increase in organizational capacity building efforts by external organizations in low and middle income countries, the documentation of these efforts and their effects on health programs and systems remains limited. This paper reviews key frameworks for considering sustainability of capacity building and applies these frameworks to an evaluation of the sustainability of an AIDS non-governmental organization (NGO) capacity building initiative. From 2004-2007 Bristol-Myers Squibb Foundation's Secure the Future(TM) initiative in southern Africa funded a five country program, the NGO Training Institute (NGOTI), to build capacity of NGOs working to address HIV/AIDS. Lessons learned (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v98/%3B%97f%FC%12%7D%7By ROME-(BUSINESS WIRE)-Bristol-Myers Squibb Company (NYSE:BMY) and Alder Biopharmaceuticals today announced that new data from a dose-ranging Phase 2a trial support further development of BMS-945429/ALD518, an investigational monoclonal antibody directed against interleukin-6 (IL-6), as a potential treatment for rheumatoid arthritis (RA). The Phase 2a data will be presented in a scientific session on June 18, 2010, at the Annual Congress of the European League against Rheumatism (EULAR). I look forward to the next phase of clinical development that will provide additional understanding of the efficacy and safety profile of this antibody. The 16-week Phase 2a study evaluated the safety and (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v98/%3B%97f%FC%12%7Cwz NEW YORK-(BUSINESS WIRE)-Bristol-Myers Squibb Company (NYSE: BMY) will present at the 2010 Wells Fargo Securities Health Care Conference on Wednesday, June 23, 2010, in Boston. John Elicker, vice president, Investor Relations, will make a formal presentation about the company at 1:30 p.m. EDT. Investors and the general public are invited to listen to a live webcast of the presentation at http:/investor.bms.com. Materials related to the presentation will be available at the same website at the start of the live webcast. An archived edition of the presentation will be available later that day. About Bristol-Myers Squibb Bristol-Myers Squibb is a global biopharmaceutical company whose (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v98/%3B%97f%FC%10%7Ews J Clin Oncol. |-| Horak CE, Harbison CT, Khambata-Ford S. |-| Bristol-Myers Squibb, Princeton, NJ. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v98/%3B%97f%FC%16%7B%7E%7E Formation of high molecular weight (HMW) species is a common issue encountered during manufacture of protein therapeutics. With advanced purification techniques, efficient removal of protein aggregates is no longer a challenging task, but it is important to minimize protein aggregation level at the culture stage to reduce the downstream burden and improve overall process yield. In this regard, our recent effort on medium optimization has led us to unexpectedly discover that glucocorticoids can significantly reduce the formation of HMW species in IgG-fusion protein produced by CHO cells. First, the effectiveness of dexamethasone can be seen at nanomolar concentrations, which allows this (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v98/%3B%97f%FC%16xx%7D The formation of malonyl-CoA is catalyzed by acetyl-CoA carboxylase (ACC), the rate-limiting enzyme of de novo fatty acid synthesis. Monitoring the changes of malonyl-CoA concentration in the brain in response to treatments such as pharmaceutical intervention (via ACC inhibitors) or different dietary conditions (such as varied feeding regimes) is of great interest and could help increase the understanding of how this molecule contributes to feeding behavior and overall energy balance. We have developed a sensitive analytical method for the determination of malonyl-CoA levels in rat brain tissue. The assay involved removal of tissue lipids by liquid-liquid extraction followed by LC/MS/MS (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v98/%3B%97f%FD%1Ctw%7D NEW YORK-(BUSINESS WIRE)-Bristol-Myers Squibb Company (NYSE: BMY) will present at the 2010 Wells Fargo Securities Health Care Conference on Wednesday, June 23, 2010, in Boston. John Elicker, vice president, Investor Relations, will make a formal presentation about the company at 1:30 p.m. EDT. text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v98/%3B%97f%FD%1Ct%7Dr ROME-(BUSINESS WIRE)-Bristol-Myers Squibb Company (NYSE:BMY - News) and Alder Biopharmaceuticals today announced that new data from a dose-ranging Phase 2a trial support further development of BMS-945429/ALD518, an investigational monoclonal antibody directed against interleukin-6 (IL-6), as a potential treatment for rheumatoid arthritis (RA). The Phase 2a data will be presented in a scientific session on June 18, 2010, at the Annual Congress of the European League against Rheumatism (EULAR). The 16-week Phase 2a study evaluated the safety and efficacy of BMS-945429/ALD518 in 132 patients with RA inadequately controlled with methotrexate. Patients were randomized to receive intravenous (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v98/%3B%97f%FD%1C%7Bx%7D RESEARCH TRIANGLE PARK, N.C. & AMSTERDAM-(BUSINESS WIRE)-Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme s novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings. œThis partnership allows us to monetize part of the value of ulimorelin, while still retaining the (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v98/%3B%97f%FD%1C%7B%7Dy ROME-(BUSINESS WIRE)-Bristol-Myers Squibb Company (NYSE:BMY) and Alder Biopharmaceuticals today announced that new data from a dose-ranging Phase 2a trial support further development of BMS-945429/ALD518, an investigational monoclonal antibody directed against interleukin-6 (IL-6), as a potential treatment for rheumatoid arthritis (RA). The Phase 2a data will be presented in a scientific session on June 18, 2010, at the Annual Congress of the European League against Rheumatism (EULAR). text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v98/%3B%97f%FD%1Cxys SEATTLE-(BUSINESS WIRE)-ZymoGenetics, Inc. (NASDAQ:ZGEN) announced today that James A. Johnson, Executive Vice President and Chief Financial Officer of ZymoGenetics, will present at the Piper Jaffray Europe Conference in London on Wednesday, June 23, 2010 at 11:00 a.m. GMT. A live webcast of the presentation can be accessed by going to: www.zymogenetics.com. The webcast will be archived for 30 days. About ZymoGenetics ZymoGenetics is a biopharmaceutical company focused on the development and commercialization of therapeutic proteins for the treatment of human diseases. The company has developed and is marketing RECOTHROM Thrombin, topical (Recombinant) in the United States. ZymoGenetics (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v98/%3B%97f%FD%1Cxz%7C DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/5028be/bristolmyers_squi) has announced the addition of the "Bristol-Myers Squibb Company - SWOT Analysis" company profile to their offering. The Bristol-Myers Squibb Company - SWOT Analysis company profile is the essential source for top-level company data and information. Bristol-Myers Squibb Company - SWOT Analysis examines the company's key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy. Bristol-Myers Squibb Company (BMS) is a global biopharmaceutical company. BMS was formed by the merger of Bristol Myers and Squibb (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v98/%3B%97f%FD%1D%7By%7C An ambient pressure ionization technique for mass spectrometric analysis of substances present on solid surfaces was developed. A nebulized spray containing molecular ions of a solvent such as toluene can be generated by passing the solvent through a stainless steel capillary held at a high voltage. When the stream of charged droplets produced in this way is directed onto a solid surface, the analytes present on the surface are desorbed and ionized by a charge exchange process. This technique was shown to desorb and generate positively charged molecular ions from compounds that are not readily ionized by some other ambient methods, under positive-ion generation mode. For example, intense (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v98/%3B%97f%FD%13xvy In vitro developmental model systems have been an important tool for advancing basic research in the embryology and teratology fields. The rat and zebrafish embryo models have had broad utility in both fields for many decades. Furthermore embryonic stem cells, applied as a basic research tool, have broad applications across the development fields and many other fields including cancer, regeneration and epigenetic research. These models have historically been applied in mechanistic studies but were also considered promising for evaluating teratogenic potential of test substances. In recent years, in vitro teratogenicity assays have become an area of interest for supporting the 3 Rs (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v98/%3B%97f%FD%11y%7Cy SAN DIEGO-(BUSINESS WIRE)-Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its Board of Directors has authorized a reverse stock split of the Company s common stock and a share repurchase program. Ligand also announced preliminary financial guidance for 2011 and updated financial guidance for 2010. œOur revenue and financial performance outlook is positive over the foreseeable future,  said John L. Higgins, President and Chief Executive Officer of Ligand Pharmaceuticals. œWe have confidence in the business and believe this is an appropriate time to reduce our bloated share count through a reverse stock split as the company moves toward profitability. A higher (…) text/html http://www.bionity.com Bionity.com http://www.lsis.com/goto/v98/%3B%97f%FD%11y%7Fy 15.06.2010 - ExonHit Therapeutics announced the signing of an exclusive agreement with Genmab A/S for a selection of novel splice variants, identified as part of a successful pilot study, that have the potential to be therapeutic targets for breast cancer. Genmab retains exclusive development and commercialization rights on 10 events out of a breast cancer database developed using ExonHit s genome-wide SpliceArray technology. "Breast cancer is the leading cause of death by cancer in women and there is still a significant need for new therapies against this disease. As already demonstrated with Allergan s recent outlicensing deal with Bristol-Myers Squibb, our genome-wide SpliceArray (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v98/%3B%97f%FD%11x%7Fy Barcelona, 12 June 2010: The BCR-ABL kinase inhibitor dasatinib (Sprycel, Bristol-Myers Squibb) achieves significantly higher rates of complete cytogenetic response and major molecular response than imatinib as first-line treatment in patients with previously untreated chronic myeloid leukaemia (CML), according to results from the randomised phase 3 DASISION trial reported at the European Hematology Association congress. The study randomised 519 adults newly diagnosed with Philadelphia chromosome positive CML to dasatinib (100mg once daily) or imatinib (400mg once daily). Results after a median follow-up period of 14 months showed that the rate of confirmed complete cytogenetic response at (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v98/%3B%97f%FD%11%7F%7E%7E LOS ANGELES-(BUSINESS WIRE)-AIDS Healthcare Foundation: Drug spending by ADAPs has increased more than seven-fold (617%) since 1996, more than twice the rate of client growth over this same period. WHAT: PROTEST Re: BMS Pricing of AIDS Drug, Reyataz, one of the most expensive first line AIDS treatments in the US WHEN: TUESDAY, June 15th, 10:00 AM Pacific WHERE: outside the Goldman Sachs Global Healthcare Conference 2010 Hyatt Regency Century Plaza Hotel 2025 Avenue of the Stars Century City, CA VISUALS: 3ft x 6ft œShame on BMS  and œHow do you spell GREED? BMS  banners & placards with image of CEO Andreotti surrounded by Piles of Cash Protestors, marching with signs and chanting (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v98/%3B%97f%FD%11%7E%7Br PRINCETON, N.J.-(BUSINESS WIRE)-Bristol-Myers Squibb Company (NYSE: BMY) today announced that it has signed agreements with ICON and PAREXEL, two leading providers of clinical development services to the biopharmaceutical industry, for joint strategic, operational and capability support of the company s clinical development program. Working with ICON and PAREXEL, two leaders in clinical research, Bristol-Myers Squibb will enhance support for our robust pipeline and improve our ability to deliver innovative medicines to patients with serious disease. Under the agreements, ICON and PAREXEL will provide global support for the execution of Bristol-Myers Squibb s clinical studies to support (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v98/%3B%97f%FD%11%7E%7E%7D PARIS-(BUSINESS WIRE)-Regulatory News: This pilot study clearly demonstrates the ability of ExonHit s technology to identify novel target candidates for breast cancer treatment approaches. ExonHit applied its genome-wide SpliceArray ¢ technology to develop a unique database in breast cancer Genmab retains exclusive rights on 10 novel splice events to fuel its antibody discovery activity ExonHit can further exploit the database to develop new drug candidates internally or through partnerships ExonHit Therapeutics (Paris:ALEHT) today announced the signing of an exclusive agreement with Genmab A/S for a selection of novel splice variants, identified as part of a successful pilot study, (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v98/%3B%97f%FD%11%7Cyr PRINCETON, N.J.-(BUSINESS WIRE)-Bristol-Myers Squibb Company (NYSE: BMY) today announced that it has signed agreements with ICON and PAREXEL, two leading providers of clinical development services to the biopharmaceutical industry, for joint strategic, operational and capability support of the company s clinical development program. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v98/%3B%97f%FD%14%7D%7B%7B In this paper, we discuss an improved high-performance liquid chromatography (HPLC) method for the quantitation of polysorbate 80 (polyoxyethylenesorbitan monooleate), a commonly used stabilizing excipient in therapeutic drug solutions. This method is performed by quantitation of oleic acid, a hydrolysis product of polysorbate 80. Using base hydrolysis, polysorbate 80 releases the oleic acid at a 1:1 molar ratio. The oleic acid can then be separated from other polysorbate 80 hydrolysis products and matrices using reversed phase HPLC. The oleic acid is monitored without derivatization using the absorbance at 195nm. The method was validated and also shown to be accurate for the quantitation (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v98/%3B%97f%FE%1Cu%7F%7F SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (NASDAQ: EXEL) announced today that George A. Scangos, PhD, the company s president and chief executive officer, will present at the Goldman Sachs 31st Annual Global Healthcare Conference at 1:20 p.m. PDT / 4:20 p.m. EDT on Tuesday June 15, 2010 in Los Angeles. Dr. Scangos will discuss the company s corporate strategy and development pipeline, and provide a general business update. The event will be webcast and may be accessed in the Event Calendar page under Investors at http:/www.exelixis.com. About Exelixis Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v98/%3B%97f%FE%12%7Dwr Bristol-Myers Squibb's plans this month to close its plant in Meymac, France, that manufactures "the last therapeutic option" for HIV-positive babies has drawn criticism from UNITAID, Reuters reports. In an open letter published in the Lancet (.pdf), UNITAID writes that "[c]losing this factory means that 4,000 to 7,000 babies currently enrolled in treatment plans in developing countries through UNITAID could be left without the medicines they need." According to Reuters, "Bristol-Myers spokeswoman Sonia Choi said production [of the medication] is expected to resume immediately upon anticipated regulatory approval of the new U.S. plant in February 2011 . Before closing, she said the (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v98/%3B%97f%FE%12%7Dv%7D PRINCETON, N.J. & NEW YORK-(BUSINESS WIRE)-Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) today announced that the companies have agreed to stop the Phase 3 AVERROES clinical trial of apixaban in patients with atrial fibrillation. The study will be stopped early because a predefined interim analysis by the independent Data Monitoring Committee (DMC) revealed clear evidence of a clinically important reduction in stroke and systemic embolism in patients with atrial fibrillation considered intolerant of or unsuitable for vitamin K antagonist therapy who received apixaban as compared to aspirin. This interim analysis also demonstrated an acceptable safety profile for (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v98/%3B%97f%FE%12%7C%7D%7B WATERTOWN, Mass.-(BUSINESS WIRE)-Wolfe Laboratories, Inc. (WLI), a biopharmaceutical development services company dedicated to community service, participated in the first-ever statewide Biotechnology Job Shadow Day by hosting twenty 11th grade students from the Boston Latin School, the oldest school in America. The future of the biotechnology industry in Massachusetts is dependent upon the presence of a qualified workforce "The partnership between the biotech industry and Massachusetts future workforce is extremely important to Wolfe Laboratories, so we were thrilled to participate in the first-ever statewide Biotechnology Job Shadow Day,  said Margarita Hunter, Head of Marketing and (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v98/%3B%97f%FE%13uw%7C DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/122efb/looking_at_the_can) has announced the addition of the "Looking at the Cancer Therapy Market" report to their offering. Cancer is a disease characterized by a population of cells that grow and divide without respect to normal limits, invade and destroy adjacent tissues, and may spread to distant anatomic sites through a process called metastasis. These life-threatening, malignant properties of cancers differentiate them from benign tumors, which are self-limited in their growth and do not invade or metastasize. Cancer may affect people at all ages, but risk for the more common varieties tends to (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v98/%3B%97f%FE%13u%7Bx NEW YORK-(BUSINESS WIRE)-The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of 32 cents ($0.32) per share on the $0.10 par value Common Stock of the corporation. The quarterly dividend will be payable on August 2, 2010 to stockholders of record at the close of business on July 2, 2010. The Directors also declared a quarterly dividend of 50 cents ($0.50) per share on the $2.00 Convertible Preferred Stock of the corporation, payable September 1, 2010 to stockholders of record at the close of business on August 6, 2010. About Bristol-Myers Squibb Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v98/%3B%97f%FE%13zyx PURPOSE We sought to determine whether the combination of ixabepilone plus capecitabine improved overall survival (OS) compared with capecitabine alone in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes. PATIENTS AND METHODS A total of 1,221 patients with MBC previously treated with anthracycline and taxanes were randomly assigned to ixabepilone (40 mg/m(2) intravenously on day 1) plus capecitabine (2,000 mg/m(2) orally on days 1 through 14) or capecitabine alone (2,500 mg/m(2) on the same schedule) given every 21 days. The trial was powered to detect a 20% reduction in the hazard ratio (HR) for death. Results There was no significant (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v98/%3B%97f%FE%13%7Fw%7C The polymorphic and/or pseudo-polymorphic phase transformation of Drug Z API, from Form I to Form II, occurs during the wet granulation step. It was observed that dissolution of the tablets slowed down under certain manufacturing conditions. Factors responsible for the slowdown in tablet dissolution were investigated in this study. Two levels of shear during premixing and two wet granulation drying temperatures were investigated by measuring the dissolution profiles of the tablets. The interaction between API and excipients was examined using differential scanning calorimetry and X-ray powder diffraction. When stearic acid was present with Form I as the starting material in the (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v98/%3B%97f%FE%10%7Fwy BACKGROUND: CASTLE compared the efficacy of atazanavir/ritonavir with lopinavir/ritonavir, each in combination with tenofovir-emtricitabine in ARV-naïve subjects from 5 continents. OBJECTIVES: Determine the baseline rate and clinical significance of TDR mutations using ultra-deep sequencing (UDS) in ARV-naïve subjects in CASTLE. METHODS: A case control study was performed on baseline samples for all 53 subjects with virologic failures (VF) at Week 48 and 95 subjects with virologic successes (VS) randomly selected and matched by CD4 count and viral load. UDS was performed using 454 Life Sciences/Roche technology. RESULTS: Of 148 samples, 141 had successful UDS (86 subtype B, 55 non-B (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v98/%3B%97f%FE%10%7E%7Dz OBJECTIVE: To study factors associated with therapeutic inertia in treating hypertension and to develop a predictive model to estimate the probability of therapeutic inertia in a given medical consultation, based on variables related to the consultation, patient, physician, clinical characteristics, and level of care. METHODS: National, multicentre, observational, cross-sectional study in primary care and specialist (hospital) physicians who each completed a questionnaire on therapeutic inertia, provided professional data and collected clinical data on four patients. Therapeutic inertia was defined as a consultation in which treatment change was indicated (i.e., SBP /= 140 or DBP /= 90 (…)